|
Imitrex DF (Sumatriptan Tablets)
Manufactured by: Glaxo Smith Kline  This product requires a valid prescription
| |
|
Type |
Strength |
|
Quantity |
|
Price (USD) |
|
|
| |
|
Health Canada has approved Imitrex DF(TM) for the treatment of migraine. The new formulation contains the original active ingredient, with the same proven efficacy and safety of the conventional Imitrex(R) tablet (sumatriptan succinate), but with an innovative technology designed to facilitate disintegration in the stomach. Imitrex(R), the first of the medications known as triptans, was approved in Canada in 1992, and continues to be the most prescribed medication of its kind. Imitrex DF tablets are swallowed whole with water and break apart in the stomach within minutes, allowing the drug to be rapidly absorbed into the bloodstream. Imitrex DF(TM) is approved for the acute treatment of migraine with or
without aura (a visual disturbance that occurs prior to the onset of migraine
pain) in adults and is available by prescription in pharmacies nationwide.
Imitrex DF should only be used when a clear diagnosis of migraine has been
established by a physician. Imitrex DF also treats the associated symptoms of migraine, including nausea, vomiting, and sensitivity to light and sound and is generally well-tolerated. Imitrex DF(TM) will replace the traditional oral tablets, to join the family of successful Imitrex(R) medications, which also includes nasal spray and injection formulations.
Migraine headaches affect three times as many women as men.
Some common migraine triggers include:
- Alcohol (especially red wine)
- Dairy products (especially cheddar cheese)
- Fatty or fried foods
- Food additives
- Shifts in weather (e.g., a sudden change in climate)
- Hormonal factors (e.g., puberty, menstruation, pregnancy,
menopause)
- Oral contraceptive use
- Stress (extreme emotions - positive or negative
|
|
|
|
